HCPLive Network

Osteoporosis Therapy Has Unclear Impact on Spinal Fusion

FRIDAY, March 1 (HealthDay News) -- The effect of osteoporosis therapies (bisphosphonate drugs and intermittent parathyroid hormone [PTH]) on spinal fusion is unclear, according to a review published in the February issue of The Spine Journal.

Brandon P. Hirsch, MD, of the University of Miami/Jackson Health System, and colleagues conducted a systematic review of the literature from 1980 to 2011 to assess the potential impact of bisphosphonates and PTH on fusion rate and quality in spinal arthrodesis. Eighteen animal studies and one clinical trial were included in the review.

The researchers found that most animal studies showed that bisphosphonates have no significant impact on fusion rate but that treatment may result in less histologically mature fusion mass; the impact of these changes on fusion mass biomechanics was unclear. Based on the human study, bisphosphonates had no impact on clinical outcome but may have increased the radiographically defined fusion rate. PTH improved the fusion rate and fusion mass microstructure in animals, but data were lacking for the effect on fusion mass biomechanics. There were no studies that assessed the impact of PTH on spine mass in humans.

"In the absence of conclusive human data relating to spine fusion, we recommend the continuation or initiation of these therapies in patients based on their indication for the treatment of osteoporosis, without regard for a recent or impending spine fusion procedure," the authors write. "However, on the basis of preclinical data, we believe that anabolic agents may offer an advantage over antiresorptive medications in osteoporotic patients undergoing spine fusion."

One author disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.
Further Reading
As more pediatric surgical procedures being conducted as same-day procedures, parents are assuming responsibility for their children’s immediate post-operative pain management.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
There is a significantly increased risk of cardiac death associated with clarithromycin use, according to a study published online Aug. 19 in BMJ.
As the 2 Americans stricken with Ebola continue to receive treatment in Atlanta, a new potential case of the deadly virus has been reported in California.
Active surveillance for clinical stage I testis cancer leads to excellent outcomes, according to a study published online Aug. 18 in the Journal of Clinical Oncology.
Pistachio consumption is associated with improvements in glucose and cardiometabolic parameters, according to a study published online Aug. 14 in Diabetes Care.
For patients with heart failure with reduced ejection fraction, cardiac resynchronization therapy and implantable cardioverter-defibrillator therapies are associated with clinical benefit, irrespective of patient race/ethnicity, according to a study published in the Aug. 26 issue of the Journal of the American College of Cardiology..
More Reading